FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL
|
Estimated average burden hours per response... | 0.5 |
|
|
(Print or Type Responses)
1. Name and Address of Reporting Person *
|
Versant Venture Capital VI, L.P. |
|
2. Issuer Name and Ticker or Trading Symbol Akero Therapeutics, Inc. [AKRO]
|
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
|
__X__ 10% Owner
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
|
ONE SANSOME STREET,, SUITE 3630 |
3. Date of Earliest Transaction (Month/Day/Year) 01/07/2020 |
SAN FRANCISCO, CA 94104 |
4. If Amendment, Date Original Filed
(Month/Day/Year) 01/09/2020 |
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
1.Title of Security (Instr. 3)
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 01/07/2020 |
| S (1) |
| 14,162 | D |
$20.05 (2) | 2,885,836 | I | See Footnote (3) |
Common Stock | 01/08/2020 |
| S (1) |
| 22,368 | D |
$19.80 (4) | 2,863,468 | I | See Footnote (3) |
Common Stock | 01/09/2020 |
| S (1) |
| 16,527 | D |
$20.21 (5) | 2,846,941 | I | See Footnote (3) |
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)
|
6. Date Exercisable and Expiration Date (Month/Day/Year)
|
7. Title and Amount of Underlying Securities (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Versant Venture Capital VI, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO, CA 94104 |
|
X
|
|
|
Versant Ventures VI GP, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO, CA 94104 |
|
X
|
|
|
Versant Ventures VI GP-GP, LLC ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO, CA 94104 |
|
X
|
|
|
Signatures
VERSANT VENTURE CAPITAL VI, L.P. By: Versant Ventures VI GP, L.P., its general partner By: Versant Ventures VI GP-GP, LLC, its general partner By: /s/ Robin L. Praeger, Managing Director | |
07/10/2020 |
**Signature of Reporting Person | Date |
VERSANT VENTURES VI GP, L.P. By: Versant Ventures VI GP-GP, LLC, its general partner Its: General Partner By: /s/ Robin L. Praeger, Managing Director | |
07/10/2020 |
**Signature of Reporting Person | Date |
VERSANT VENTURES VI GP-GP, LLC By: /s/ Robin L. Praeger, Managing Director | |
07/10/2020 |
**Signature of Reporting Person | Date |
Explanation of Responses:
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan. |
(2) | These sales were executed in multiple trades at prices ranging from $19.77 to $20.73. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. |
(3) | These shares are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein. |
(4) | These sales were executed in multiple trades at prices ranging from $19.81 to $20.19. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. |
(5) | These sales were executed in multiple trades at prices ranging from $19.82 to $20.41. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. |
Remarks: This Form 4/A to the Form 4 filed with the Securities and Exchange Commission on January 9, 2020 is being amended and restated in its entirety to correct the aggregate number of securities beneficially owned by Versant VI in Table I, Column 5. As a result of the transactions reported herein, the Reporting Persons no longer beneficially own greater than 10% of the outstanding shares of the Issuer, and therefore are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended. This filing constitutes an exit filing for the Reporting Persons. |
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
|